PRES Secondary to the LenvatinibPembrolizumab Combination in a Patient with Serous Endometrial Adenocarcinoma
Open Access
- 11 September 2023
- journal article
- research article
- Published by Gavin Publishers in International Journal of Cerebrovascular Disease and Stroke
- Vol. 6 (1)
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub) acute onset characterized by varied neurological symptoms [1].Keywords
This publication has 4 references indexed in Scilit:
- Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancerFrontiers in Oncology, 2023
- Posterior Reversible Encephalopathy Syndrome: A Review of the LiteratureInternal Medicine, 2022
- Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001International Journal of Gynecological Cancer, 2022
- Detecting the Uncommon Imaging Manifestations of Posterior Reversible Encephalopathy Syndrome (PRES) in Adults: a Comprehensive Illustrated Guide for the Trainee RadiologistCurrent Problems in Diagnostic Radiology, 2022